Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: A systematic review and meta-analysis

American Journal of Therapeutics

Volumn 16, Issue 2, 2009, Pages 133-142

  Balamuthusamy, Saravanan ^a   Molnar, Janos ^a   Adigopula, Sasikanth ^a   Arora, Rohit ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Beta blocker; Blockade agents; Cardiovascular outcomes; Diabetes with hypertension; RAS

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; PLACEBO; VERAPAMIL;

ARTICLE; CLINICAL TRIAL; CONTROL GROUP; DIABETES MELLITUS; DIABETIC PATIENT; HEART INFARCTION; HUMAN; HYPERTENSION; MANTEL HAENSZEL TEST; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK; RISK FACTORS;

EID: 64549155333     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31817fd87e     Document Type: Article

References (29)

1. Rinfret S, Abrahamowicz M, Tu J, et al. A population-based analysis of the class effect of B-blockers after myocardial infarction. Am Heart J. 2007;153:224-230.
2. Haeusler G. Pharmacology of beta-blockers: classical aspects and recent developments. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S1-S9.
3. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;1: CD002003.
4. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
5. Gottlieb SS, McCarter RJ, Vogel RA, et al. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339:489-497.
6. Jacoby R, Nesto R. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20:736-744.
7. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561-572.
8. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltia-zem (NORDIL) study. Lancet. 2000;356:359-365.
9. Black HR, Elliott WJ, Grandits G, et al, for the CONVINCE Research Group. Results of the Controlled ONset Verapamil INvestigation of ardiovascular End-points (CONVINCE) trial by geographical region. J Hypertens. 2005;23:1099-1106.
10. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
11. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003;290: 2805-2816.
13. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
14. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
15. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289: 2073-2082.
16. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Circulation. 1995; 92:3132-3137.
17. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100:1254-1262.
18. Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension. 2007;50:459-460.
19. Gasse C, Jacobsen J, Larsen AC, et al. Secondary Medical Prevention among Danish Patients Hospitalised with Either Peripheral Arterial Disease or Myocardial Infarction. Eur J Vase Endovasc Surg. 2007;33:26-32.
20. Holman R, Turner R, Stratton I, et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
21. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens. 2000;14:541-546.
22. Hoffmann U, Globits S, Stefenelli T, et al. The effects of ACE inhibitor therapy on left ventricular myocardial mass and diastolic filling in previously untreated hypertensive patients: a Cine MRI study. J Magn Reson Imaging. 2001;14:16-22.
23. Bakris GL, Fonseca V, et al, for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes melhtus and hypertension. JAMA. 2004;292:2227-2236.
24. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
25. Aronson D, Rayfield E, Cheseboro J. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 1997;126:296-306.
26. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Intern Med. 2001;134:370-379.
27. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901-906.
28. Bakris GL, Ruilope L, Locatelli F, et al. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006;20:693-700.
29. Norris K, Bourgoigne J, Gassman J, et al, and the AASK Study Group. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739-751.